Behnood Bikdeli

Anticoagulants for Atrial Fibrillation in Survivors of Intracranial Hemorrhage: A Meta-Analysis of Randomized Trials: @JACCJournals 🥸 New publication from our HeartWise research Group led by friend: @MichaelGNanna in JACC today! 😱Summary 👇👇👇

Great News: @GregoryPiazza4 @bbikdeli will present HI-PRO at @escardio #ESC2025 on August 31th!

The weather’s not the only thing heating up…the July edition of What’s Hot in Clots is here! 🔥☀️💥 @bbikdeli brings you the latest: 🩸COBRRA: Apixaban > rivaroxaban for bleeding risk in VTE 🔷SPECTACULAR: Imaging in PE 📖New ACS guidelines in @JACCJournals 🧪PCC > plasma…

#2 One of my @ISTH presentations was simultaneously published! 📄 thieme-connect.com/products/ejour… > Incorporating Present-On-Admission indicators into ICD-10 codes improves accuracy of PE identification from claims data Thanks to the collaborators & mentors! #Thrombosis #HealthData

#RivaGate in DC at ⁦@isth⁩ 2025 In COPRRA, apixaban was substantially safer than rivaroxan for initial (3 mo) treatment of VTE. 🙏🙏🙏 ⁦@LanaCastellucci⁩ for this arguably most important DOAC study ever ⁦@bbikdeli⁩ ⁦@isabellemahe1⁩ ⁦@LaurentBertole1⁩

Choosing a Long-Term Antiplatelet Regimen After Percutaneous Coronary Intervention Results from a meta-analysis of five randomized trials of P2Y12 inhibitors versus aspirin monotherapy: jwat.ch/3Twuqek @bbikdeli #CardioTwitter

Important info RE safety of #XI/XIa inhibitors in @JACCJournals study of peri-procedural 🩸 @SidPatelMD @TIMIStudyGroup jacc.org/doi/10.1016/j.… w a nice Editorial by experts: tinyurl.com/6uhawb4b In an Editor's note, I share hope & ? RE efficacy. 👇 tinyurl.com/ycycumcn

💜 How we talk about blood clots matters. 💜 🏥 The VTE Communication Guide was created to help clinicians navigate the complex conversations that follow a venous thromboembolism (VTE) diagnosis from risk and treatment to emotions and uncertainty. ❤️ This project brings…

Antiplatelet or anticoagulant? The new ACS guideline decodes the chaos with clarity. A must-read roadmap for frontline care 🧭 jacc.org/doi/10.1016/j.… #JACC #cvACS #ClinicalGuidelines @Drroxmehran @djc795 @bbikdeli @hmkyale

Not unexpected. LLMs can help us write discharge summaries. Let’s make sure clinicians help shape their implementation and ensure a patient-first innovation.

We summarized the guideline recs for #anticoagulant& #antiplatelettherapy in ACS & compared them w prior recs in @ACCinTouch @AHAScience & @escardio guidelines. 🙏🙏 Writing Committee and also a great team who made this summary possible 👇👇: jacc.org/doi/10.1016/j.…

🌞 June is here, bringing warmer weather and something else that's "hot"... our June edition of What's Hot In Clots, of course! Here's a quick look at some intriguing updates in cardiovascular and thrombotic care this month: 🔹 Intraprocedural ACT Targets in PCI: Do we finally…

🚨🚨Now there is a full issue of @JACCJournals dedicated to the new @ACCinTouch @AHAScience guideline for #ACS!! 👇 jacc.org/toc/jacc/curre… @SVRaoMD @DrM_ODonoghue @hmkyale

Among 889 with colon cancer s/p resection & adjuvant chemotherapy, RCT shows that a 3y structured exercise program vs health education alone showed 28% relative improvement in disease-free survival at 7.9y nejm.org/doi/full/10.10… @NEJM (coverage nytimes.com/2025/06/01/wel……

Need to do better for #PE risk stratification, beyond reductionist models. In an @ESC_Journals #EHJ paper we show that a multimarker calculator🌡️outperforms the ESC model. Great work by @DJC6998 @mmonrealriete et al #RIETE! Honored to be a part of it 👇: tinyurl.com/trpmzbrd

Thanks so much @CardioUva for the opportunity to visit for #CV GrandRounds. Wonderful connecting w old friends, making new ones, & connecting w @UVACardsFellows. Look forward to further collaborations. Despite the ⛈️, Zocalo was awesome!😄@ChrisKramerMD @AbbateAntonio

We're back with another exciting edition of What's Hot In Clots! 💜 This month we delve into the considerations for Factor V Leiden testing. Do we really need to test for Factor V Leiden as often as we do? 📚 A recent JAMA piece makes a strong case: in most scenarios —…

𝐂𝐇𝐀𝐌𝐏𝐈𝐎𝐍𝐒 𝐋𝐄𝐀𝐆𝐔𝐄 𝐅𝐈𝐍𝐀𝐋: ℎ𝑒𝑟𝑒 𝑤𝑒 𝑐𝑜𝑚𝑒 🔥 #ForzaInter #UCL #InterBarcellona

LLM-generated discharge summaries were of comparable quality to those generated by physicians, though they contained more errors, and both types had low overall harmfulness scores. ja.ma/44XgLUC

From Head to Toe, Take Control. Did you know that 1 in 4 people worldwide die from conditions caused by blood clots? Thrombosis is a leading cause of death—and yet, it’s often preventable with awareness and timely care. 🔗 Get involved today: worldthrombosisday.org